- Actinogen Medical (ACW) completes final participant visits for the XanaMIA Part A trial which the company says will provide analysis of the effects of its Xanamem technology
- Xanamem is designed as an oral therapeutic for Alzheimers Disease and other neurological diseases
- The trial consisted of 107 volunteers with the aim of evaluating the efficacy, safety and pharmacodynamics of a 5 mg Xanamem dosing level
- The company says the data will be used to design the company’s future Alzheimer’s Disease clinical program
- Shares have been down 4.17 per cent, trading at 11.5 cents
Actinogen Medical (ACW) has completed final participant visits for the XanaMIA Part A trial, which the company says will provide an analysis of the effects of its Xanamem technology.
Xanamem is designed as an oral therapeutic for Alzheimer’s Disease and other neurological diseases.
Xanamem’s novel mechanism of action works by blocking the production of intracellular cortisol through the inhibition of a potentially harmful enzyme in the brain.
The treatment is designed to get into the brain after it is absorbed in the intestines upon
swallowing its capsule.
The trial consisted of 107 volunteers with the aim of evaluating the efficacy, safety and pharmacodynamics of a 5 mg Xanamem dosing level.
The company says the data will be used to design the company’s future Alzheimer’s Disease clinical program.
The clinical data for the dosing program are scheduled to be released in April 2022.
Actinogen Medical CEO and Managing Director Steven Gourlay said the company is excited by the date, which has the potential to save lives in the future.
“Xanamem has the potential to be a novel daily oral therapy for Alzheimer’s Disease and other neurological diseases that could be used alone or in combination with other therapies to help make a difference to the lives of patients and their families living with serious neurological conditions,” he said.
Shares were down 4.17 per cent, trading at 11.5 cents at 11.47 am AEDT.